Cargando…

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan

The purpose of the present study was to assess the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan against locally advanced lower rectal cancer according to UDP‐glucuronosyltransferase 1A1 (UGT1A1) polymorphisms. Between 2009 and 2016, 46 patients with resectable rectal canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Kei, Yamano, Tomoki, Igeta, Masataka, Imada, Ayako, Jihyung, Song, Babaya, Akihito, Hamanaka, Michiko, Kobayashi, Masayoshi, Tsukamoto, Kiyoshi, Noda, Masafumi, Ikeda, Masataka, Tomita, Naohiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272094/ https://www.ncbi.nlm.nih.gov/pubmed/30246377 http://dx.doi.org/10.1111/cas.13807

Ejemplares similares

Malnutrition in rectal cancer patients receiving preoperative chemoradiotherapy is common and associated with treatment tolerability and anastomotic leakage
por: Yamano, Tomoki, et al.
Publicado: (2016)

Evaluation of appropriate follow-up after curative surgery for patients with colorectal cancer using time to recurrence and survival after recurrence: a retrospective multicenter study
por: Yamano, Tomoki, et al.
Publicado: (2018)

Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan
por: Yamano, Tomoki, et al.
Publicado: (2017)

Combination of preoperative tumour markers and lymphovascular invasion with TNM staging as a cost and labour efficient subtyping of colorectal cancer
por: Yamano, Tomoki, et al.
Publicado: (2020)

Prognostic significance of classified extramural tumor deposits and extracapsular lymph node invasion in T3–4 colorectal cancer: a retrospective single-center study
por: Yamano, Tomoki, et al.
Publicado: (2015)

Assessment of circulating microRNA specific for patients with familial adenomatous polyposis
por: Yamano, Tomoki, et al.
Publicado: (2021)

Metastatic lobular carcinoma of the breast masquerading as a primary rectal cancer
por: Matsuda, Ikuo, et al.
Publicado: (2012)

Impact of preoperative chemoradiotherapy using concurrent S-1 and CPT-11 on long-term clinical outcomes in locally advanced rectal cancer
por: Kimura, Kei, et al.
Publicado: (2020)

A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)
por: Sato, Takeo, et al.
Publicado: (2016)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy
por: Yamano, Tomoki, et al.
Publicado: (2019)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature
por: Argevani, Lia, et al.
Publicado: (2020)

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
por: Iwasa, Satoru, et al.
Publicado: (2021)

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
por: TSUNEDOMI, RYOUICHI, et al.
Publicado: (2014)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
por: Li, Minmin, et al.
Publicado: (2014)

Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China
por: Yi, Lang, et al.
Publicado: (2016)

Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
por: Bai, Yu, et al.
Publicado: (2017)

Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
por: Tsunedomi, Ryouichi, et al.
Publicado: (2017)

A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma
por: Yamano, Tomoki, et al.
Publicado: (2020)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
por: Liu, X, et al.
Publicado: (2014)

The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
por: Xiao, Xiao-guang, et al.
Publicado: (2015)

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism
por: Jannin, Arnaud, et al.
Publicado: (2017)

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28
por: Tian, Chuan, et al.
Publicado: (2018)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Anatomical Validation of Internal Iliac Vessels Assessed by Three-dimensional Angiographic Analysis
por: Takenaka, Yuya, et al.
Publicado: (2023)

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
por: Matsuoka, Hideki, et al.
Publicado: (2020)

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
por: Nakano, Shintaro, et al.
Publicado: (2020)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
por: Chen, Shaojun, et al.
Publicado: (2020)

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
por: Lee, Choong-kun, et al.
Publicado: (2022)

A review of preoperative chemoradiotherapy for lower rectal cancer
por: Beppu, Naohito, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q3749ikm90d6rjc05hn4271029